We previously demonstrated that losartan and its anti–TGF-β metabolite EXP3179, which has no angiotensin receptor–blocking properties, could reverse TGF-β1–induced mucociliary dysfunction in an ovine model of CF-like airway disease in vivo and in CF bronchial epithelial (CFBE) cells in the absence of highly effective CFTR modulators in vitro (17). This evidence concerns the gene TGFB1 and cystic fibrosis.